GlassScriptPhysician profile
David M Obriant
NPI 1124292214
$1,610.21
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $455 · 2021: $28.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $391.80 | 2019-2020 | |
| Allergan, INC. | $143.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $141.22 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $134.49 | 2019 | |
| Pfizer INC. | $106.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $91.87 | 2019-2020 | |
| Melinta Therapeutics, LLC | $91.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $82.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.80 | 2019-2020 | |
| Electromed, INC. | $64.17 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.36 | 2020 | |
| Merck Sharp & Dohme LLC | $44.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.94 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.54 | 2019-2020 | |
| Amgen INC. | $21.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Obriant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.